THIS EXECUTIVE EMPLOYMENT AGREEMENT is dated for reference the 1st day of February, 2002. BETWEEN: IMMUNE NETWORK LTD., having an office at 3650 Wesbrook Mall, Vancouver, British Columbia, V6S 2L2 (the "Company") AND: ALLEN BAIN, of 2039 MacDonald...Executive Employment Agreement • July 16th, 2002 • Immune Network LTD • Services-commercial physical & biological research • British Columbia
November 21, 2001Immune Network LTD • July 16th, 2002 • Services-commercial physical & biological research
This letter (the "Agreement") is intended to record the general terms and conditions of our mutual agreement concerning the grant by Immune Network Ltd. ("IMM") to InNexus, Inc. ("InNexus") of an exclusive sublicense option to the intellectual properties for the monoclonal ant ibodies hNM01 and 1F7 and concerning a convertible loan from IMM to InNexus. All currency references in this Agreement are to U.S. dollars.
THIS DEBT SETTLEMENT AGREEMENT made as of March 18, 2002. BETWEEN: Immune Network Ltd. of 202 1768 West 3rd Avenue, Vancouver, British Columbia, V6J 1K4 (Telefax No. (604) 733-6631) (hereinafter called the "Creditor")Debt Settlement Agreement • July 16th, 2002 • Immune Network LTD • Services-commercial physical & biological research
InNexus Inc., a company duly incorporated pursuant to the laws of the state of Washington and having its offices at 2198 South Bay Vista Lane, Camano Island, Seattle, Washington, 98282 (Telefax No. (425) 696-0068)
CONSULTANT AGREEMENTConsultant Agreement • July 16th, 2002 • Immune Network LTD • Services-commercial physical & biological research • New York
This Agreement is made and entered into as of the 31st day of January, 2002, between Immune Network Ltd. (the "Company") and Rachel Glicksman ("Consultant").
SHARE PURCHASE AGREEMENT CROMEDICA INTERNATIONAL INC. AND IMMUNE NETWORK LTD. SHARE PURCHASE AGREEMENTShare Purchase Agreement • July 16th, 2002 • Immune Network LTD • Services-commercial physical & biological research • British Columbia
NOW THEREFORE, in consideration of the mutual covenants herein after set forth and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
Re: Letter of Intent Regarding Dapsone Controlled Delivery Technology ProductImmune Network LTD • July 16th, 2002 • Services-commercial physical & biological research
This non-binding letter of intent summarizes the agreement in principle between Immune Network Ltd. ("Immune Network") and Nutraceutix, Inc. ("Nutraceutix") regarding the possible development, manufacture and marketing of an anti-inflammatory and anti-microbial product containing dapsone as the active pharmaceutical ingredient and incorporating Nutraceutix's proprietary Controlled Delivery TechnologyiM ("CDT"), which Nutraceutix will license to Immune Network. Immune Network and Nutraceutix have agreed in principle as follows:
Re: Consulting Services Agreement Dated January 31, 2002Immune Network LTD • July 16th, 2002 • Services-commercial physical & biological research • New York
We refer to our Consulting Services Agreement dated for reference January 31, 2002 (the "Agreement"), pursuant to which you, the Consultant, have agreed to provide certain Services to the Company. All initially capitalized terms used herein will have the respective meanings assigned thereto in the Agreement.
